AR126199A1 - Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos - Google Patents

Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos

Info

Publication number
AR126199A1
AR126199A1 ARP220101632A ARP220101632A AR126199A1 AR 126199 A1 AR126199 A1 AR 126199A1 AR P220101632 A ARP220101632 A AR P220101632A AR P220101632 A ARP220101632 A AR P220101632A AR 126199 A1 AR126199 A1 AR 126199A1
Authority
AR
Argentina
Prior art keywords
til population
tumor
population
cryopreserved
disaggregated
Prior art date
Application number
ARP220101632A
Other languages
English (en)
Inventor
Sunetra Biswas
Original Assignee
Instil Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Inc filed Critical Instil Bio Inc
Publication of AR126199A1 publication Critical patent/AR126199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos para determinar la potencia de linfocitos infiltrantes de tumores (TIL) aislados y expandidos y para producir poblaciones terapéuticas de TIL, así como composiciones que los comprenden y métodos de tratamiento con los mismos. Reivindicación 1: Un método para evaluar la potencia de linfocitos infiltrantes de tumores (TIL) contra células cancerosas, caracterizado porque comprende: a) obtener una población aislada y expandida ex vivo de los TIL; b) cocultivar la población de los TIL con células diana modificadas que activan las células T a través de CD3 para preparar una población de TIL activada; c) agregar a la población de TIL activada, un anticuerpo anti-CD107a marcado con fluorescencia o un fragmento de unión a antígeno del mismo, un anticuerpo anti-CD2 marcado con fluorescencia o un fragmento de unión a antígeno del mismo, y un anticuerpo anti-IFN-g marcado con fluorescencia o un fragmento de unión a antígeno del mismo; d) detectar la presencia o ausencia de células T CD2+ viables que expresan uno o ambos entre: a. IFN-g, y b. CD107a; y, e) determinar el porcentaje de potencia de la población de TIL activada. Reivindicación 99: Un método para preparar una población terapéutica de linfocitos infiltrantes de tumores (TIL), caracterizado porque comprende: a) desagregar de manera aséptica un tumor extirpado de un sujeto para preparar de esa manera un producto de tumor desagregado, en donde la desagregación comprende aplicar repetidamente presión física entre 120 y 360 veces por minuto a como máximo 6 N/cm² en presencia de un medio de una solución de enzimas, en donde el tumor está suficientemente desagregado en una suspensión de células como para que el producto de tumor desagregado se pueda criopreservar; b) dentro de las 24 horas de preparar el producto de tumor desagregado, enfriar el producto de tumor desagregado hasta una temperatura de criopreservación adecuada para preparar un producto de tumor desagregado criopreservado; c) guardar el producto de tumor desagregado criopreservado en un estado congelado; d) descongelar el producto de tumor desagregado criopreservado; e) realizar una primera expansión mediante el cultivo del producto de tumor desagregado criopreservado en un medio de cultivo celular que comprende IL-2 para producir una primera población de TIL; f) realizar una segunda expansión mediante cultivo de la primera población de TIL en un medio de cultivo celular con IL-2 adicional, OKT-3 y células presentadoras de antígenos (APC), para producir una segunda población de TIL; y g) criopreservar la segunda población de TIL para preparar una población terapéutica de TIL criopreservada; en donde los pasos (a), (b), (c), (d), (e), (f) y (g) se conducen en un sistema cerrado; h) obtener una muestra de la segunda población de TIL del paso f) o una muestra de la población terapéutica de TIL criopreservada del paso g); i) cocultivar la población de los TIL del paso h) con células del tumor para preparar una población de TIL activada; j) agregar a la población de TIL activada, un anticuerpo anti-CD107a marcado con fluorescencia o un fragmento de unión a antígeno del mismo, un anticuerpo anti-CD2 marcado con fluorescencia o un fragmento de unión a antígeno del mismo, y un anticuerpo anti-IFN-g marcado con fluorescencia o un fragmento de unión a antígeno del mismo k) detectar la presencia o ausencia de células T CD2+ viables que expresan uno o ambos entre: a. IFN-g, y b. CD107a; y, l) determinar el porcentaje de potencia de la población de TIL activada.
ARP220101632A 2021-06-24 2022-06-22 Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos AR126199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163214735P 2021-06-24 2021-06-24

Publications (1)

Publication Number Publication Date
AR126199A1 true AR126199A1 (es) 2023-09-27

Family

ID=84545943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101632A AR126199A1 (es) 2021-06-24 2022-06-22 Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos

Country Status (4)

Country Link
EP (1) EP4358978A1 (es)
AR (1) AR126199A1 (es)
TW (1) TW202317756A (es)
WO (1) WO2022271881A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532078A4 (en) * 2016-10-31 2020-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. ARTIFICIAL ANTIGEN PRESENT CELLS USED FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
KR20210064269A (ko) * 2018-09-20 2021-06-02 이오반스 바이오테라퓨틱스, 인크. 동결보존된 종양 샘플로부터의 til의 확장
IL294098A (en) * 2019-12-20 2022-08-01 Instil Bio Uk Ltd Devices and methods for isolating lymphocytes infiltrating tumors and their use

Also Published As

Publication number Publication date
TW202317756A (zh) 2023-05-01
WO2022271881A1 (en) 2022-12-29
EP4358978A1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
Zarandi et al. Cryostorage of immature and mature human testis tissue to preserve spermatogonial stem cells (SSCs): a systematic review of current experiences toward clinical applications
Nichane et al. Isolation and 3D expansion of multipotent Sox9+ mouse lung progenitors
Chen et al. Chondrogenic differentiation of umbilical cord-derived mesenchymal stem cells in type I collagen-hydrogel for cartilage engineering
Brinkley et al. Procedure for embedding in situ selected cells cultured in vitro
Oktay et al. Ovarian cryopreservation and transplantation: basic aspects
Yunger et al. Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy
EA201270213A1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
Glass et al. Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets
Chen et al. Optimal timing of blastocyst vitrification after trophectoderm biopsy for preimplantation genetic screening
Pasley et al. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media
Matas et al. Evaluation of a cushioned method for centrifugation and processing for freezing boar semen
AR126199A1 (es) Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos
Hosseini et al. Improvement of motility after culture of testicular spermatozoa: the effects of incubation timing and temperature
Nation et al. The production of mature oocytes from adult ovaries following primary follicle culture in a marsupial
ES2825723T3 (es) Método para utilizar células directoras para la activación y diferenciación de células madre/progenitoras específicas
Yeh et al. Spermatogonial stem cell biomarkers: improved outcomes of spermatogonial transplantation in male fertility restoration?
Amirkhani et al. Mini bioreactor can support in vitro spermatogenesis of mouse testicular tissue
Zhang et al. A high-quality biobank supports breast cancer research in Harbin, China
Johnson et al. Physiology of Bacteria-free Trichomonas vaginalis. VII: Temperature in Relation to Survival and Generation Time.
Karabon et al. Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
Özdemir Evaluation of human mast cell-mediated cytotoxicity by DIOC18 target cell labeling in flow cytometry
AR126198A1 (es) Procesamiento de linfocitos infiltrantes de tumores
ATE463582T1 (de) Screening-verfahren zur identifizierung neuer aminoacyl-trna-synthetase-inhibitoren
Veneziani et al. Issues of banking breast cancer cells to generate mammospheres

Legal Events

Date Code Title Description
FB Suspension of granting procedure